Stockholders Approve Significant Increase in Equity Plan Shares
ASMB sits 47% above its 52-week low of $15.54.
Summary
Assembly Biosciences stockholders approved an increase of 1.49 million shares for its stock incentive and employee stock purchase plans, representing potential future dilution of approximately $34 million.
Key Events · Financing and Capital Events · ASMB
-
Stock Incentive Plan Expanded
Stockholders approved an increase of 1,200,000 shares for the 2018 Stock Incentive Plan, raising the total reserved shares to 2,678,333. This follows the proxy statement filed on April 22, 2026, which sought this approval.
-
Employee Stock Purchase Plan Expanded
Stockholders approved an increase of 290,000 shares for the ESPP, raising the total reserved shares to 515,000. This also follows the proxy statement filed on April 22, 2026.
-
Board of Directors Elected
All nine director nominees were elected to serve until the 2027 annual meeting.
-
Executive Compensation Approved
Stockholders approved the named executive officers' compensation on a non-binding advisory basis.
Analysis · ASMB · Life Sciences
Shareholders approved a substantial increase in shares reserved for the company's stock incentive plan and employee stock purchase plan. This authorization of an additional 1.49 million shares, representing approximately $34 million at current prices, creates significant potential future dilution for existing shareholders as these shares are issued over time for employee compensation.
At the time of this filing, ASMB was trading at $22.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $452.8M. The 52-week trading range was $15.54 to $39.71. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.